# Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir

> **NCT03236584** · PHASE3 · UNKNOWN · sponsor: **Uijeongbu St. Mary Hospital** · enrollment: 76 (actual)

## Conditions studied

- Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48

## Interventions

- **DRUG:** lamivudine plus adefovir combination
- **DRUG:** Tenofovir Disoproxil Fumarate

## Key facts

- **NCT ID:** NCT03236584
- **Lead sponsor:** Uijeongbu St. Mary Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-09-01
- **Primary completion:** 2018-03-30
- **Final completion:** 2019-03-30
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236584, "Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03236584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*